Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > ORGANIZATION
ORGANIZATION
- 9 Pharma-Related Companies to Join to Global Health Innovative Technology Fund
June 8, 2016
- Japan Is at Crossroads, Must Carry On Its Pro-Innovation Policies: PhRMA Chairman
June 3, 2016
- PhRMA Still “Concerned” about Anti-Innovation Policies despite Tax Decision: Japan Chief
June 2, 2016
- Biosimilar Policies Shouldn’t Threaten Biologics Development: EFPIA Japan
May 31, 2016
- Astellas’s Hatanaka Elected as New JPMA President
May 27, 2016
- Sumitomo Dainippon Pres. Tada Picked as New Chief of FPMAJ
May 27, 2016
- No Need to Add Hep B Vaccines to Public Immunization Program: Drug Damage Watchdog
May 13, 2016
- Citizen’s Group Says Kaketsuken Shouldn’t Profit from Suspension-Cleared Products, Surcharges Needed
May 13, 2016
- EFPIA Takes to Nagata-cho to Call for Real Dialogue
April 28, 2016
- National Univ. Hospital Council to Disclose Funding with Companies’ Names Not Affiliated with JPMA
April 27, 2016
- JPMA Official Calls for Use of Academic Data in Drug Submissions
April 26, 2016
- Quakes Injure 3, Cause Property Damage for 22 Companies: JPMA Survey
April 20, 2016
- JPMA Sets Up Taskforce for Russia, Brazil, Mexico, Turkey
April 18, 2016
- Contract Sales Reps in Japan Likely to Increase to 6,000 in 2021: Industry Group
April 15, 2016
- Japan at a Crossroads as Investment Destination, World’s Eyes Riveted on Govt’s Signals: PhRMA Local Chief
April 13, 2016
- EFPIA Japan Chief to Call for “Real Dialogue” at Today’s Public-Private Policy Confab
April 12, 2016
- Asian Industry Groups Agree to Continue Efforts to Improve Access to Innovative Medicines in Asia
April 11, 2016
- Front-Loaded Price Cuts Necessary for Drugs Like Opdivo: JMA’s Nakagawa
April 7, 2016
- Japan Pharma Groups Step Up Lobbing Campaigns to Skirt Further Drug Cost Cuts
April 7, 2016
- Generic Use Rate at 56.1% in October-December 2015: JGA
April 1, 2016
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…